Automated Infectious Disease and Vaccine Trial Protocol Design Workflow

By ingesting and interpreting WHO, CDC, and EMA guidance updates in real-time, the workflow autonomously drafts protocol sections for challenge studies, immunogenicity assessments, and variant surveillance. This reduces the design phase from months to weeks, enabling sponsors to initiate trials before pathogen evolution or public interest shifts, capturing critical early efficacy data.

Manual drafting often leads to internal inconsistencies and regulatory misalignment, discovered late in the process. A custom workflow embeds rule-based validation (e.g., checking dose escalation logic against ICH S9, ensuring endpoint alignment with FDA CBER guidance) and medical review checkpoints. This proactively flags contradictions, reducing amendment-driven delays and rework that can cost over $500k per event and set back timelines by 3-6 months.

The workflow simulates recruitment by analyzing real-world data on disease incidence, demographic factors, and historical trial performance for similar pathogens. It generates more precise inclusion/exclusion criteria and site selection recommendations, de-risking enrollment—the primary cause of trial delays. This leads to faster site activation and higher probability of meeting recruitment targets.

Automating the assembly of boilerplate sections (background, study design), safety monitoring plans (DSMB charters), and lab manuals frees senior medical writers and clinicians for high-value strategic review. The workflow integrates with document systems (Veeva Vault) and generates submission-ready drafts, reducing manual drafting effort by 70% and cutting total FTEs required for protocol development.

Every decision in the AI-generated protocol is traceable to a source guideline, historical trial data point, or internal rule. The workflow maintains a complete audit trail of changes, rationales, and review approvals. This creates a defensible submission package for FDA/EMA, streamlining interactions with regulators and reducing questions during review, which can shorten the overall IND/CTA approval cycle.

For sponsors managing multiple vaccine or antiviral programs, the workflow provides a consistent, repeatable design process. It allows rapid scenario modeling (e.g., pandemic vs. seasonal strain, pediatric expansion) and generates comparable protocol structures. This improves portfolio decision-making and operational leverage, enabling teams to launch more trials with the same headcount and budget.

A dedicated agent continuously monitors and parses updates from WHO, CDC, EMA, and FDA for emerging pathogen guidance, variant surveillance requirements, and immunogenicity standards. It converts this unstructured text into structured, machine-readable rules and templates, ensuring the protocol generation engine operates on the latest public health intelligence. This component eliminates the 2-3 week manual research lag that typically delays protocol initiation during outbreaks.

Orchestrated agents (e.g., using LangGraph) specialize in distinct protocol sections: one drafts the challenge study or vaccination schedule, another authors the immunogenicity assessment plan, and a third generates the variant surveillance and genomic sequencing strategy. A master orchestrator manages context passing, resolves conflicts, and ensures logical consistency across sections, producing a cohesive first draft that incorporates study design best practices from a historical trial knowledge graph.

A rule-based validation engine runs the draft protocol against a library of regulatory constraints (ICH GCP, regional ethics requirements) and operational feasibility checks (site capability, patient recruitment modeling for rare pathogens). It flags inconsistencies, missing safety monitoring for novel adjuvants, or unrealistic visit schedules. This layer acts as a pre-review QC step, catching issues that typically cause major amendments, reducing rework cycles by an estimated 40%.

The workflow integrates with document management systems (e.g., Veeva Vault) to route draft sections to specific human reviewers based on expertise—infectious disease MDs, vaccinologists, biostatisticians. It presents draft text alongside the source guidelines and validation flags, providing clear context for review. Automated reminders and version diffing keep the review cycle on track, compressing the typical 4-6 week collaborative review into a 10-day structured process.

Upon final approval, an assembly agent compiles all approved modules, applies sponsor-specific formatting templates, manages cross-references, and generates a submission-ready PDF or eCTD-compliant package. It ensures version control integrity and creates an immutable audit trail linking every protocol statement to its source guidance and review approval. This eliminates the final manual assembly and quality check that often takes a week, delivering a production-ready document in hours.

The custom build typically involves a microservices backend (Python/FastAPI) hosting the agent orchestration, connected via APIs to source systems: regulatory intelligence feeds, internal historical protocol repositories, and downstream clinical systems (EDC, RTSM). A front-end portal provides medical writers and study leads with a controlled interface to trigger generation, monitor progress, and intervene. Deployment is often containerized (Docker/K8s) for scalability, with strict access controls and full observability (logging, tracing) for regulated environments.

Medical/Regulatory Affairs: Gains 60-70% faster draft generation and automated compliance checks against ICH/FDA/EMA guidelines, reducing pre-submission rework. Clinical Operations: Sees cycle time from synopsis to final protocol drop from 12+ weeks to 3-4 weeks, accelerating site activation. Biostatistics & Data Management: Receives structured, machine-readable protocol outputs that auto-populate SAP and EDC specifications, cutting manual translation work by 50%. Project Leadership: Achieves predictable timelines, lower amendment risk, and real-time visibility into design trade-offs via integrated dashboards.

Phase 1 (Pilot): Deploy for a single, non-critical vaccine trial protocol (e.g., a booster study). Integrate with Veeva Vault or SharePoint for document management and use a sandboxed LLM orchestration layer (LangGraph). Validate output quality against a manually created gold-standard protocol. Phase 2 (Expansion): Extend to a therapeutic area (e.g., respiratory viruses), incorporating pathogen-specific WHO/CDC guidance agents. Connect to clinical trial management system (CTMS) for feasibility feedback loops. Phase 3 (Scale): Roll out across infectious disease portfolio, integrating with regulatory intelligence platforms and electronic data capture (EDC) systems for end-to-end specification generation.

Medical Review Gates: Mandatory human sign-off on final inclusion/exclusion criteria, primary endpoints, and safety monitoring plans before system finalization. Change Audit Trail: Every AI-suggested edit is logged with rationale, reviewer identity, and approval status, creating a defensible record for regulators. Exception Routing: The workflow automatically flags low-confidence sections (e.g., novel endpoint definitions) and routes them to designated therapeutic area experts for manual resolution. Model Performance Monitoring: Continuous tracking of draft acceptance rates, amendment triggers post-implementation, and user feedback to retrain and improve agentic logic.

Orchestration Core: LangGraph or custom agent framework to manage sequential drafting agents (eligibility, endpoints, safety), validation bots, and document assemblers. Data Ingestion: Connectors to internal historical protocol repositories, regulatory guideline databases (FDA Gateway, EMA), and real-world evidence platforms. Output Systems: APIs to push structured protocol data to CTMS for feasibility, to EDC (Medidata Rave) for CRF build, and to document management systems (Veeva) for version control. Legacy Consideration: The workflow must accommodate PDF/Word-based inputs from older systems and output human-editable formats, avoiding a 'black box' that stifles iterative review.

Role-Based UIs: Provide different interfaces for medical writers (full editing), reviewers (comment/approve), and operational staff (status tracking). Training on 'AI-Assisted' Drafting: Shift mindset from authoring from scratch to editing and validating high-quality AI drafts. Focus training on exception handling and oversight. Metrics-Driven Buy-in: Publicize pilot results on time saved, reduction in QC comments, and faster IRB submission dates to build organizational momentum. Process Integration: Embed the workflow into existing SOPs for protocol development, ensuring it becomes the single source of truth rather than a parallel, optional tool.

Data Quality & Hallucination: Implement rigorous retrieval-augmented generation (RAG) from trusted sources (internal libraries, official guidelines) and rule-based validation for numerical logic and consistency. Regulatory Scrutiny: Design the system to produce detailed 'explainability' reports showing the source guidance for each protocol section, ready for regulatory queries. Rollback Protocol: Maintain the ability to revert to a fully manual process for high-risk, first-in-class trials if the system's confidence scores fall below a defined threshold. Vendor Lock-in Avoidance: Build on open-source orchestration frameworks where possible and ensure proprietary LLM APIs are abstracted, allowing model swapping as technology evolves.